India News Magazine

RNAi Therapeutics Market projected to reach US$ 1,209.29 million by 2027 and to grow at a CAGR of 8.8%

 Breaking News
  • No posts were found

RNAi Therapeutics Market projected to reach US$ 1,209.29 million by 2027 and to grow at a CAGR of 8.8%

March 05
18:33 2021
RNAi Therapeutics Market projected to reach US$  1,209.29 million by 2027 and to grow at a CAGR of 8.8%

RNAi Therapeutics Market
RNAi therapeutics market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027.

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes that are responsible for diseases. At present, the awareness about RNAi is increasing due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the RNAi Therapeutics market growth during the forecast period.However, high cost involved in the development of RNAi therapies is likely to restraint the growth of the market during the forecast years.

Based on application, the global RNAi therapeutics market is segmented into oncology, cardiovascular, respiratory disorders, renal diseases, genetic disorders, neurodegenerative disorders, infectious diseases, and others. The oncology segment held the largest share of the market in 2019; whereas, the cardiovascular segment is estimated to register the highest CAGR in the market during the forecast period. Factors such as increasing prevalence of cardiovascular diseases coupled with rising demand for superior alternative for the treatment of cardiovascular conditions is expected to boost the segment growth. Moreover, increasing research and development activities in order to validate the feasibility of RNAi therapies for cardiovascular conditions are projected to drive the cardiovascular application segment.

Get Sample Report, All Related Graphs & Charts @ https://www.theinsightpartners.com/sample/TIPRE00007157/

Unlock new opportunities in Global RNAi Therapeutics Market ; the latest release from The Insight partners Research highlights the key market trends significant to the growth prospects, Let us know if any specific players or list of players needs to consider to gain better insights.

Alnylam Pharmaceuticals, Inc.; Sanofi, Olix Pharmaceuticals, Inc.; Glaxosmithkline Plc.; Benitec Biopharma; Arbutus Biopharma Corporation; Silence Therapeutics; Rexahn Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc; and Quark are among the leading companies operating in the RNAi therapeutics market.

The global impacts of COVID-19 are being felt across several markets. In case of pharmaceutical industry, supply chain operations are significantly hampered due to the pandemic. However, market players in the RNAi therapeutics are focusing on the development of vaccine with the help of gene silencing technology, which might have a positive impact on the market growth during the forecast period.

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes that are responsible for diseases. At present, the awareness about RNAi is increasing due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the market growth during the forecast period. However, high cost of RNAi therapy development is anticipated to hamper the market growth.

The effectiveness of the outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in September 2018, Curamir Therapeutics, Inc. received initial financial aid of US$ 10 million from Delos Capital to develop miRNA-based drugs for chemotherapy-resistant cancer. Also, in April 2019, Alnylam Pharmaceuticals Inc. announced its strategic partnership with Regeneron Pharmaceuticals to discover and commercialize RNAi therapeutic platform for the treatment of diseases associated with eye, central nervous system, and liver. The companies have invested about US$ 1 billion in the collaboration.

Dicerna Pharmaceuticals, Inc. received an upfront payment of ~US$ 175 million from Novo Nordisk for the initiation of the project. Furthermore, according to the terms in partnership, Dicerna Pharmaceuticals, Inc. will receive nearly US$ 25 million annually from Novo Nordisk for the first three years for the development of the product. Such investments help biotech and pharma companies not only launch new products but also increase the number of approved products. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received an approval from the US Food and Drug Administration (FDA) for its Onpattro infusion therapy used for the treatment of peripheral nerve disease (polyneuropathy).

To comprehend Global RNAi Therapeutics market dynamics in the world mainly, the worldwide RNAi Therapeutics market is analyzed across major global regions.

  • North America: United States, Canada, and Mexico.
  • South & Central America: Argentina, Chile, and Brazil.
  • Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa.
  • Europe: UK, France, Italy, Germany, Spain, and Russia.
  • Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Purchase Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPRE00007157/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: [email protected]

Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/indoreonlinejour/indianewsmagazine.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share